Avid Bioservices Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Avid Bioservices şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.1%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.1%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Aug 26

Avid Bioservices, Inc. (NASDAQ:CDMO) Surges 43% Yet Its Low P/S Is No Reason For Excitement

Jul 29

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 40% Share Price Rise

Mar 07

We Think Avid Bioservices (NASDAQ:CDMO) Has A Fair Chunk Of Debt

Feb 28

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 39% Share Price Rise

Dec 28

Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Nov 10

Calculating The Intrinsic Value Of Avid Bioservices, Inc. (NASDAQ:CDMO)

Oct 15

Time To Worry? Analysts Are Downgrading Their Avid Bioservices, Inc. (NASDAQ:CDMO) Outlook

Jun 23

Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Jun 12

Little Excitement Around Avid Bioservices, Inc.'s (NASDAQ:CDMO) Earnings As Shares Take 26% Pounding

May 21

Avid Bioservices GAAP EPS of $0.02 beats by $0.01, revenue of $36.7M beats by $3.26M

Sep 06

Laughing Water Capital - Avid Bioservices: Not A Binary Bet But A Real Business

Jul 27

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CDMO şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CDMO şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Avid Bioservices Piyasaya Karşı Temettü Getirisi

CDMO temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CDMO)	n/a
Pazarın Alt %25'i (US)	1.3%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (CDMO) (3 yıla kadar)	n/a

Önemli Temettü: CDMO şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CDMO şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CDMO şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CDMO herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Avid Bioservices Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Punch and Associates Sends Letter to Board of Directors of Avid Bioservices, Inc

Funds managed by GHO Capital Partners LLP and Ampersand Management LLC entered into a definitive merger agreement to acquire Avid Bioservices, Inc. (NasdaqCM:CDMO) for approximately $850 million.

Funds managed by GHO Capital Partners LLP and Ampersand Management LLC entered into a definitive merger agreement to acquire Avid Bioservices, Inc. (NasdaqCM:CDMO) for approximately $850 million.

President exercised options and sold US$173k worth of stock

Consensus EPS estimates fall by 29%

Avid Bioservices, Inc. Reiterates Earnings Guidance for the Fiscal Year 2025

Price target increased by 14% to US$14.00

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Avid Bioservices, Inc. to Report Q1, 2025 Results on Sep 09, 2024

Avid Bioservices, Inc., Annual General Meeting, Oct 16, 2024

Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Avid Bioservices, Inc. (NASDAQ:CDMO) Surges 43% Yet Its Low P/S Is No Reason For Excitement

Consensus EPS estimates fall by 21%

Full year 2024 earnings: EPS misses analyst expectations

Avid Bioservices Provides Earnings Guidance for Fiscal Year 2025

Avid Bioservices, Inc. to Report Fiscal Year 2024 Final Results on Jul 02, 2024

Insufficient new directors

Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q

Avid Bioservices, Inc. announced delayed 10-Q filing

Avid Bioservices, Inc. announced that it expects to receive $160 million in funding

Avid Bioservices, Inc. Maintains Revenue Guidance for Full Fiscal Year 2024

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 40% Share Price Rise

Avid Bioservices, Inc. announced that it expects to receive $160 million in funding

We Think Avid Bioservices (NASDAQ:CDMO) Has A Fair Chunk Of Debt

Insufficient new directors

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 39% Share Price Rise

Director recently bought US$135k worth of stock

Consensus EPS estimates fall by 121%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Avid Bioservices, Inc. Revises Revenue Guidance for the Full Fiscal Year 2024

Avid Bioservices, Inc. to Report Q2, 2024 Results on Dec 07, 2023

Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Avid Bioservices, Inc. (NASDAQ:CDMO)

Independent Chairman recently bought US$191k worth of stock

Consensus EPS estimates fall by 139%

Price target decreased by 7.2% to US$19.25

Avid Bioservices, Inc. Reiterates Revenue Guidance for Full Fiscal Year 2024

Avid Bioservices, Inc. to Report Q1, 2024 Results on Sep 07, 2023

Avid Bioservices, Inc., Annual General Meeting, Oct 23, 2023

President exercised options and sold US$254k worth of stock

Price target decreased by 11% to US$19.75

President exercised options and sold US$519k worth of stock

Consensus revenue estimates fall by 14%

Time To Worry? Analysts Are Downgrading Their Avid Bioservices, Inc. (NASDAQ:CDMO) Outlook

New minor risk - Profit margin trend

Full year 2023 earnings: EPS misses analyst expectations

Avid Bioservices, Inc. to Report Q4, 2023 Results on Jun 21, 2023

Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Little Excitement Around Avid Bioservices, Inc.'s (NASDAQ:CDMO) Earnings As Shares Take 26% Pounding

Investor sentiment deteriorates as stock falls 15%

Are Investors Undervaluing Avid Bioservices, Inc. (NASDAQ:CDMO) By 49%?

Insider notifies of intention to sell stock

Independent Director recently sold US$142k worth of stock

Director exercised options and sold US$69k worth of stock

Chief Financial Officer notifies of intention to sell stock

Third quarter 2023 earnings released

Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Investor sentiment deteriorates as stock falls 18%

Consensus EPS estimates fall by 217%

Director exercised options and sold US$60k worth of stock

Director exercised options and sold US$57k worth of stock

Independent Director recently sold US$87k worth of stock

President exercised options and sold US$117k worth of stock

Consensus forecasts updated

Director exercised options and sold US$116k worth of stock

Avid Bioservices, Inc. Revises Revenue Guidance for the Full Fiscal Year 2023

Avid Bioservices, Inc. to Report Q2, 2023 Results on Dec 06, 2022

Here's Why Avid Bioservices (NASDAQ:CDMO) Has A Meaningful Debt Burden

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Director exercised options and sold US$69k worth of stock

Consensus forecasts updated

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Avid Bioservices, Inc. Provides Revenue Guidance for the Fiscal 2023